First Phase III Pivotal Trial
Symyoo expanded its business into a full scope CRO and began to operate a first phase III trial for premature ejaculation study.
symyoo
SYMYOO Founded
Dongjin Yoo, CEO & MD, founded a CRO to help K-Bio industry’s clinical development after his successful journey as a CEO and medical director of many global pharmaceuticals and bio startups.